NCI Definition: An adenocarcinoma arising from the uterine body cavity. This is the most frequent malignant tumor affecting the uterine body, and is linked to estrogen therapy. Most patients present with uterine bleeding and are over age 40 at the time of diagnosis. The prognosis depends on the stage of the tumor, the depth of the uterine wall invasion, and the histologic subtype. Endometrioid adenocarcinoma is the most frequently seen morphologic variant of endometrial adenocarcinoma. [1]

Endometrial adenocarcinomas most frequently harbor alterations in PIK3CA, PTEN, ARID1A, TP53, and PIK3R1 [2].

Most Commonly Altered Genes in Endometrial Adenocarcinoma

PIK3CA Mutation, PTEN Mutation, ARID1A Mutation, TP53 Mutation, and TP53 Missense are the most common alterations in endometrial adenocarcinoma [2].

Top Alterations in Endometrial Adenocarcinoma

Significant Genes in Endometrial Adenocarcinoma




MLH1 +

MLH3 +

MSH2 +

MSH3 +

MSH6 +

PMS1 +

PMS2 +


Disease Details

Adenocarcinoma of Endometrium, Adenocarcinoma of the Endometrium, UTERUS ENDOMETRIAL ADENOCARCINOMA (NOS), ADENOCARCINOMA, ENDOMETRIAL, MALIGNANT
Endometrial Carcinoma
Endometrial Endometrioid Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Mixed Adenocarcinoma, and Endometrial Clear Cell Adenocarcinoma


1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.